- ►diabetesjournals.org [PDF] MB Schulze, K Hoffmann - Diabetes Care, 2005 - Am Diabetes Assoc The National Cholesterol Education Program (NCEP) guidelines recom- mend use of
statin-fibrate combina- tions to treat combined dyslipidemia. Myopathy and
rhabdomyolysis are re- ported side effects, especially with gemfi- ... Cited by 55 - Related articles - All 8 versions
ME Mcgovern - The British Journal of Diabetes & Vascular Disease, 2004 - dvd.sagepub.com Page 1. http://dvd.sagepub.com The British Journal of Diabetes & Vascular Disease
DOI: 10.1177/14746514040040020301 2004; 4; 78 British ... Cited by 16 - Related articles - All 6 versions
E Bruckert, M Baccara-Dinet, F McCoy, J … - Current Medical Research and Opinion®, 2005 - informahealthcare.com Objective: Low HDL-cholesterol is a strong independent cardiovascular risk
factor recognized as a therapeutic target in recent guidelines. The Pan-European
Survey on HDL-cholesterol collected data on plasma lipid profiles from 8545 ... Cited by 49 - Related articles - BL Direct - All 5 versions
[CITATION] European Consensus Panel on HDL-C. Raising high-density lipoprotein cholesterol with …
A Vogt, U Kassner, U Hostalek, E Steinhagen … - Vascular Health and Risk Management, 2007 - pubmedcentral.nih.gov Low HDL-cholesterol (<1.02 mmol/L [40 mg/dL] in men or <1.29 mmol/L [50 mg/dL]
in women) occurs in about one-third of European patients with dyslipidemia and
is an independent cardiovascular risk factor. Simultaneous correction of ... Cited by 8 - Related articles - BL Direct - All 6 versions
- ►ahajournals.org [PDF] H Drexel, FW Amann, J Beran, K Rentsch, R … - Circulation, 1994 - Am Heart Assoc Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone:
410-528-4050. Permissions: Permissions & Rights Desk, Lippincott Williams &
Wilkins, a division of Wolters ... Heinz Drexel, MD; Franz W. Amann, MD; ... Cited by 74 - Related articles - BL Direct - All 4 versions
PL Canner, CD Furberg, ML Terrin, ME … - The American journal of cardiology, 2005 - Elsevier The Coronary Drug Project, conducted during 1966 to 1974, was a randomized,
double-blind, placebo-controlled trial of 5 lipid-modifying agents in 8,341 men
with previous myocardial infarction. 1 Among the 5 drug treatment regimens, ... Cited by 111 - Related articles - All 12 versions
[CITATION] AHA Scientific Statement. Prevention Conference V. Beyond secondary prevention: identifying …
JR Guyton - eop, 2004 - informahealthcare.com Niacin (nicotinic acid) favourably modifies all aspects of the lipoprotein pro-
file; it raises high-density lipoprotein cholesterol (HDL-C) levels, lowers
trig- lyceride, low-density lipoprotein cholesterol (LDL-C) and ... Cited by 36 - Related articles - All 4 versions
CH Saely, L Koch, F Schmid, T Marte, S Aczel, … - European Journal of Clinical Investigation, 2006 - pt.wkhealth.com Results: At baseline, Lp(a) was significantly lower in patients with type 2
diabetes (T2DM) (n = 136) than in nondiabetic individuals (11 (0·8-30) mg dL -1
vs. 16 (0·8-51) mg dL -1 ; P = 0·025). Prospectively, Lp(a) was a strong ... Cited by 17 - Related articles - BL Direct - All 5 versions
